

Ju Dong Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1357869/publications.pdf>

Version: 2024-02-01

107
papers

7,243
citations

101496

36
h-index

60583

81
g-index

121
all docs

121
docs citations

121
times ranked

9469
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Characteristics and Outcomes of Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 670-680.e18.	2.4	22
2	Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis. <i>Hepatology</i> , 2023, 77, 546-557.	3.6	12
3	Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 183-193.	2.4	15
4	Therapeutic Underuse and Delay in Hepatocellular Carcinoma: Prevalence, Associated Factors, and Clinical Impact. <i>Hepatology Communications</i> , 2022, 6, 223-236.	2.0	8
5	Decreasing Trend of Serum Î±-Fetoprotein Level in Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1177-1179.e4.	2.4	13
6	Cachexia is Prevalent in Patients With Hepatocellular Carcinoma and Associated With Worse Prognosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1157-e1169.	2.4	12
7	Circulating Tumor Cell-Based Messenger RNA Scoring System for Prognostication of Hepatocellular Carcinoma: Translating Tissue-Based Messenger RNA Profiling Into a Noninvasive Setting. <i>Liver Transplantation</i> , 2022, 28, 200-214.	1.3	8
8	MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. <i>Journal of Hepatology</i> , 2022, 76, 781-787.	1.8	67
9	A prospective trial to evaluate the performance of the multitarget hepatocellular carcinoma blood test (mt-HBT) for screening at-risk patients: The Altus study.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS486-TPS486.	0.8	0
10	Multi-target blood test to improve the performance of hepatocellular carcinoma surveillance programs: A modeling-based virtual trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 405-405.	0.8	1
11	Early detection of primary liver cancer using plasma cell-free DNA fragmentomics: Do all the pieces come together?. <i>Hepatology</i> , 2022, 76, 289-291.	3.6	1
12	HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. <i>Journal of Hepatology</i> , 2022, 77, 128-139.	1.8	139
13	Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. <i>Hepatology</i> , 2022, 76, 1649-1659.	3.6	18
14	Circulating tumor cells: A step toward precision medicine in hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1179-1190.	1.4	7
15	Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017-2018. <i>Hepatology Communications</i> , 2022, 6, 2253-2261.	2.0	13
16	Emerging drugs for the treatment of hepatocellular carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 141-149.	1.0	4
17	Hepatic sinusoidal obstruction syndrome due to tacrolimus in a liver-transplantation recipient. <i>Gastroenterology Report</i> , 2021, 9, 485-487.	0.6	4
18	Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 73, 422-436.	3.6	200

#	ARTICLE	IF	CITATIONS
19	Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors. <i>Journal of the American College of Surgeons</i> , 2021, 232, 361-371.	0.2	23
20	Sex differences in age at waitlist registration for liver transplantation with nonalcoholic steatohepatitis as primary indication. <i>Clinical Transplantation</i> , 2021, 35, e14163.	0.8	0
21	Nuclear size of circulating tumor cells in advanced prostate cancer to reveal a potential biomarker for clinical outcomes and androgen receptor indifference.. <i>Journal of Clinical Oncology</i> , 2021, 39, 167-167.	0.8	1
22	Covalent Chemistry-Mediated Multimarker Purification of Circulating Tumor Cells Enables Noninvasive Detection of Molecular Signatures of Hepatocellular Carcinoma. <i>Advanced Materials Technologies</i> , 2021, 6, 2001056.	3.0	4
23	Transarterial Radioembolization Versus Systemic Treatment for Hepatocellular Carcinoma with Macrovascular Invasion: Analysis of the U.S. National Cancer Database. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1692-1701.	2.8	9
24	Liver Mass in a Young Male With Ollier Disease. <i>Gastroenterology</i> , 2021, 161, e4-e5.	0.6	0
25	Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis. <i>Liver Cancer</i> , 2021, 10, 407-418.	4.2	17
26	Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 1922-1932.	1.9	15
27	A morphological subset of circulating tumor cells in advanced prostate cancer reveals a potential biomarker for clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2021, 39, e17008-e17008.	0.8	0
28	DNA Methylation Markers for Detection of Cholangiocarcinoma: Discovery, Validation, and Clinical Testing in Biliary Brushings and Plasma. <i>Hepatology Communications</i> , 2021, 5, 1448-1459.	2.0	8
29	BALAD and BALAD-2 predict survival of hepatocellular carcinoma patients: a North American cohort study. <i>Hpb</i> , 2021, 23, 762-769.	0.1	11
30	High Neutrophil-Lymphocyte Ratio and Delta Neutrophil-Lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	8
31	The Role of Extracellular Vesicles in Disease Progression and Detection of Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 3076.	1.7	30
32	Diagnostic Criteria and LI-RADS for Hepatocellular Carcinoma. <i>Clinical Liver Disease</i> , 2021, 17, 409-413.	1.0	18
33	State-Level HCC Incidence and Association With Obesity and Physical Activity in the United States. <i>Hepatology</i> , 2021, 74, 1384-1394.	3.6	26
34	The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1531-1541.	3.0	43
35	Abstract 764: Circulating tumor cell-based mRNA scoring system for prognostication of hepatocellular carcinoma - Translating HCC tissue-based mRNA profiling into a non-invasive setting. , 2021, , .		0
36	Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States. <i>Hepatology</i> , 2021, 74, 2622-2632.	3.6	31

#	ARTICLE	IF	CITATIONS
37	Estrogen-Driven Growth of Focal Nodular Hyperplasia: Truth or Myth?. <i>ACG Case Reports Journal</i> , 2021, 8, e00531.	0.2	5
38	Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 479.	1.8	15
39	Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C. <i>Transplantation Direct</i> , 2021, 7, e635.	0.8	4
40	Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 974-983.	2.4	16
41	Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 71, 907-916.	3.6	123
42	REPLY:. <i>Hepatology</i> , 2020, 72, 362-363.	3.6	0
43	Reply. <i>Hepatology</i> , 2020, 72, 364-365.	3.6	0
44	Single-cell mass cytometry on peripheral blood identifies immune cell subsets associated with primary biliary cholangitis. <i>Scientific Reports</i> , 2020, 10, 12584.	1.6	13
45	New advances in the diagnosis and management of hepatocellular carcinoma. <i>BMJ, The</i> , 2020, 371, m3544.	3.0	210
46	Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring. <i>Nature Communications</i> , 2020, 11, 4489.	5.8	134
47	Knowledge, Attitudes, and Behaviors of Viral Hepatitis Among Recent African Immigrants in the United States: A Community Based Participatory Research Qualitative Study. <i>Frontiers in Public Health</i> , 2020, 8, 25.	1.3	14
48	Increase in Alcoholic Hepatitis as an Etiology for Liver Transplantation in the United States: A 2004-2018 Analysis. <i>Transplantation Direct</i> , 2020, 6, e612.	0.8	5
49	Circulating tumor cells with small nuclear size: A novel biomarker for survival and clinical outcomes in advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17512-e17512.	0.8	0
50	Association of very small nuclear circulating tumor cell (vsnCTC) with clinical outcomes in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 168-168.	0.8	0
51	Feasibility of circulating tumor DNA testing in hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 745-750.	0.6	17
52	A global view of hepatocellular carcinoma: trends, risk, prevention and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 589-604.	8.2	2,482
53	Circulating Tumor DNA and Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2019, 39, 452-462.	1.8	27
54	Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA. <i>Theranostics</i> , 2019, 9, 7239-7250.	4.6	59

#	ARTICLE	IF	CITATIONS
55	Screening Indications and Treatments for Cholangiocarcinoma. <i>Current Hepatology Reports</i> , 2019, 18, 408-416.	0.4	2
56	Current status of hepatocellular carcinoma detection: screening strategies and novel biomarkers. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986912.	1.4	70
57	Optimal endoscopy timing according to the severity of underlying liver disease in patients with acute variceal bleeding. <i>Digestive and Liver Disease</i> , 2019, 51, 993-998.	0.4	17
58	Early Detection of Hepatocellular Carcinoma: Expanding the Utility of Circulating Tumor Markers. <i>Hepatology</i> , 2019, 69, 1855-1857.	3.6	6
59	GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 531-538.	1.1	135
60	Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey. <i>Journal of Viral Hepatitis</i> , 2019, 26, 596-602.	1.0	67
61	The incidence rates and survival of gallbladder cancer in the USA. <i>European Journal of Cancer Prevention</i> , 2019, 28, 1-9.	0.6	36
62	Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 335-343.	4.5	42
63	Does cirrhosis associated with well controlled viral hepatitis confer a risk for extrahepatic cancer?. <i>Hepatology</i> , 2018, 68, 1217-1219.	3.6	2
64	Risk of Post-transplant Hepatocellular Carcinoma Recurrence Is Higher in Recipients of Livers From Male Than Female Living Donors. <i>Annals of Surgery</i> , 2018, 268, 1043-1050.	2.1	18
65	Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy. <i>Liver International</i> , 2018, 38, 136-143.	1.9	58
66	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1684.	2.4	0
67	Risk of posttransplant hepatocellular carcinoma recurrence is greater in recipients with higher platelet counts in living donor liver transplantation. <i>Liver Transplantation</i> , 2018, 24, 44-55.	1.3	23
68	Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. <i>Hepatology</i> , 2018, 68, 78-88.	3.6	45
69	More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. <i>Liver International</i> , 2018, 38, 895-902.	1.9	27
70	Green tea consumption: A potential chemopreventive measure for hepatocellular carcinoma?. <i>Hepatology</i> , 2018, 67, 10-12.	3.6	5
71	Hypothyroidism is associated with worse outcomes of hepatocellular carcinoma patients after liver transplantation. <i>Cancer Medicine</i> , 2018, 7, 5870-5878.	1.3	14
72	Management of Combined Hepatocellular Carcinoma-Cholangiocarcinoma. <i>Current Hepatology Reports</i> , 2018, 17, 385-391.	0.4	1

#	ARTICLE	IF	CITATIONS
73	Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma. <i>Seminars in Liver Disease</i> , 2018, 38, 160-169.	1.8	50
74	Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 103-111.	3.7	177
75	Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1085-1092.	1.1	43
76	Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis?. <i>Gut</i> , 2017, 66, 4-5.	6.1	5
77	Factors Influencing Surveillance for Hepatocellular Carcinoma in Patients with Liver Cirrhosis. <i>Liver Cancer</i> , 2017, 6, 126-136.	4.2	23
78	Recent Trends in the Epidemiology of Hepatocellular Carcinoma in Olmsted County, Minnesota. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 742-748.	1.1	29
79	Damned if you do, damned if you don't: The evolving story of de novo and recurrent hepatocellular carcinoma amongst those treated with direct-acting antivirals for hepatitis C virus. <i>Liver International</i> , 2017, 37, 809-811.	1.9	2
80	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. <i>Cell Reports</i> , 2017, 18, 2780-2794.	2.9	416
81	Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 767-775.e3.	2.4	112
82	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1814.	2.4	1
83	<i>Sleeping Beauty</i> Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors. <i>Cancer Research</i> , 2017, 77, 6576-6588.	0.4	40
84	Early age at diagnosis of hepatocellular carcinoma in sub-Saharan Africa – Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 394.	3.7	2
85	Reply to: "Interferon-free therapy of hepatitis C during wait list and post transplant risk of hepatocellular carcinoma recurrence", <i>Journal of Hepatology</i> , 2017, 67, 1357.	1.8	0
86	Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 127-131.e2.	2.4	66
87	Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States. <i>Cancer</i> , 2017, 123, 81-89.	2.0	46
88	Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 65, 859-860.	1.8	123
89	Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma. <i>Hepatology</i> , 2016, 63, 148-158.	3.6	72
90	Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis. <i>American Journal of Gastroenterology</i> , 2016, 111, 1573-1580.	0.2	61

#	ARTICLE	IF	CITATIONS
91	A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2016, 64, 85-91.	3.6	128
92	Weekend Admission for Acute Cholangitis Does Not Adversely Impact Clinical or Endoscopic Outcomes. <i>Digestive Diseases and Sciences</i> , 2016, 61, 53-61.	1.1	11
93	Role of admission serum albumin levels in patients with intracerebral hemorrhage. <i>Acta Neurologica Belgica</i> , 2016, 116, 27-30.	0.5	32
94	Reply. <i>Hepatology</i> , 2015, 61, 1094-1094.	3.6	2
95	Hepatocellular Carcinoma Occurs at an Earlier Age in Africans, Particularly in Association With Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2015, 110, 1629-1631.	0.2	68
96	Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling. <i>PLoS ONE</i> , 2014, 9, e92273.	1.1	49
97	Metformin does not improve survival in patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 15750.	1.4	33
98	Efficacy and Safety of Transarterial Radioembolization Versus Chemoembolization in Patients With Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2013, 36, 714-723.	0.9	125
99	Biliary Tract Cancers in Olmsted County, Minnesota, 1976-2008. <i>American Journal of Gastroenterology</i> , 2012, 107, 1256-1262.	0.2	68
100	Surveillance for Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 16-21.	2.4	31
101	Hepatocellular Carcinoma in Olmsted County, Minnesota, 1976-2008. <i>Mayo Clinic Proceedings</i> , 2012, 87, 9-16.	1.4	39
102	Model to estimate survival in ambulatory patients with hepatocellular carcinoma. <i>Hepatology</i> , 2012, 56, 614-621.	3.6	83
103	Factors That Affect Risk for Hepatocellular Carcinoma and Effects of Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 617-623.e1.	2.4	116
104	Cirrhosis Is Present in Most Patients With Hepatitis B and Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 64-70.	2.4	216
105	The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets. <i>Seminars in Cancer Biology</i> , 2011, 21, 35-43.	4.3	322
106	Epidemiology and Management of Hepatocellular Carcinoma. <i>Infectious Disease Clinics of North America</i> , 2010, 24, 899-919.	1.9	166
107	Utility of Serum YKL-40 as a Tumor-Specific Marker of Hepatobiliary Malignancies. <i>Gut and Liver</i> , 2010, 4, 537-542.	1.4	4